Free shipping on qualifying orders

Primary product image

A synthetic pentadecapeptide derived from a gastric protective protein, studied for tissue repair and angiogenic signalling. Lyophilised powder, research grade. (Placeholder listing — specifications pending verification.)

Axion Peptides compounds are synthesised to pharmaceutical-grade specifications and verified by independent HPLC analysis prior to release.

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in a gastric protective protein. It is provided as a lyophilized powder for research use only.

What is BPC-157 studied for in research?

Preclinical studies investigate BPC-157 in the context of tissue repair, angiogenic signaling, tendon and ligament models, and gastrointestinal protection, primarily in rodent and in-vitro systems.

How is BPC-157 different from TB-500?

Both are studied in recovery and tissue-remodeling research, but they are distinct molecules with different mechanisms. BPC-157 is a gastric-derived pentadecapeptide, while TB-500 is a fragment based on the actin-binding protein thymosin beta-4.

What does the Certificate of Analysis verify?

Each batch ships with a third-party COA confirming identity by mass spectrometry and purity by HPLC, along with the measured peptide content for the lot.

How should BPC-157 be reconstituted and stored?

Reconstitute with bacteriostatic water, swirling gently rather than shaking. Store lyophilized vials at -20 C; refrigerate reconstituted material at 2-8 C and avoid repeated freeze-thaw cycles.

Is BPC-157 approved for human use?

No. BPC-157 is not FDA approved and is sold strictly for in-vitro and laboratory research. It is not for human or veterinary consumption.

BPC-157 | Axion Peptides